PPIA and neoplasm: Potential reasons for the impressive safety profile may be due to the metronomic nature of RAS or MAPK pathway inhibition in healthy cells as compared to the sustained response in tumor cells (100), the enrichment of cyclophilin A in tumor cells (97), or the ability of RMC-7977 to specifically target the GTP-bound ON state of RAS.